{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:17:56Z","timestamp":1765808276243,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00277-023-05452-7","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T20:25:15Z","timestamp":1695068715000},"page":"3369-3381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7923-8972","authenticated-orcid":false,"given":"Guangyang","family":"Weng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingya","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guopan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongjun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinquan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziwen","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"5452_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner H, Weisdorf DJ, Bloomfield CD (2015) Acute myeloid leukemia. N Engl J Med 373:1136\u20131152","journal-title":"N Engl J Med"},{"key":"5452_CR2","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1080\/10428194.2017.1330956","volume":"59","author":"JA Webster","year":"2018","unstructured":"Webster JA, Pratz KW (2018) Acute myeloid leukemia in the elderly: therapeutic options and choice. Leuk Lymphoma 59:274\u2013287","journal-title":"Leuk Lymphoma"},{"key":"5452_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/joim.13293","volume":"290","author":"VL Lazarevic","year":"2021","unstructured":"Lazarevic VL (2021) Acute myeloid leukaemia in patients we judge as being older and\/or unfit. J Intern Med 290:279\u2013293","journal-title":"J Intern Med"},{"key":"5452_CR4","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/joim.13553","volume":"292","author":"M J\u00e4dersten","year":"2022","unstructured":"J\u00e4dersten M, Lilienthal I, Tsesmetzis N et al (2022) Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial. J Intern Med 292:925\u2013940","journal-title":"J Intern Med"},{"key":"5452_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377","journal-title":"Blood"},{"key":"5452_CR6","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126:291\u2013299","journal-title":"Blood"},{"key":"5452_CR7","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1080\/10428194.2018.1443328","volume":"59","author":"J Huang","year":"2018","unstructured":"Huang J, Hong M, Zhu Y et al (2018) Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia. Leuk Lymphoma 59:2570\u20132579","journal-title":"Leuk Lymphoma"},{"key":"5452_CR8","first-page":"5792","volume":"12","author":"M Hong","year":"2020","unstructured":"Hong M, Zhu H, Sun Q et al (2020) Decitabine in combination with low-dose cytarabine, aclarubicin and G-CSF tends to improve prognosis in elderly patients with high-risk AML. Aging (Albany, NY.) 12:5792\u20135811","journal-title":"Aging (Albany, NY.)"},{"key":"5452_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7\u201317","journal-title":"Blood"},{"key":"5452_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med 383:617\u2013629","journal-title":"N Engl J Med"},{"key":"5452_CR11","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SJ, Hou JZ et al (2019) Venetoclax Combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study. J Clin Oncol 37:1277\u20131284","journal-title":"J Clin Oncol"},{"key":"5452_CR12","first-page":"10","volume":"9","author":"K Yamada","year":"1995","unstructured":"Yamada K, Furusawa S, Saito K et al (1995) Concurrent use of granulocyte colony-stimulating factor with low-dose cytosine arabinoside and aclarubicin for previously treated acute myelogenous leukemia: a pilot study. Leukemia 9:10\u201314","journal-title":"Leukemia"},{"key":"5452_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ajh.20903","volume":"83","author":"W Zhang","year":"2008","unstructured":"Zhang W, Wang F, Chen Y et al (2008) Combination chemotherapy with low-dose cytarabine, homoharringtonine, and granulocyte colony-stimulating factor priming in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol 83:185\u2013188","journal-title":"Am J Hematol"},{"key":"5452_CR14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00432-010-0947-z","volume":"137","author":"L Gu","year":"2011","unstructured":"Gu L, Zhang W, Wang F et al (2011) Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia. J Cancer Res Clin 137:997\u20131003","journal-title":"J Cancer Res Clin"},{"key":"5452_CR15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1756-8722-4-46","volume":"4","author":"G Wei","year":"2011","unstructured":"Wei G, Ni W, Chiao JW, Cai Z, Huang H, Liu D (2011) A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol 4:46","journal-title":"J Hematol Oncol"},{"key":"5452_CR16","doi-asserted-by":"publisher","first-page":"e164238","DOI":"10.1371\/journal.pone.0164238","volume":"11","author":"M Xie","year":"2016","unstructured":"Xie M, Jiang Q, Li L et al (2016) HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the treatment of acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis with 2,314 participants. PLoS ONE 11:e164238","journal-title":"PLoS ONE"},{"key":"5452_CR17","doi-asserted-by":"publisher","first-page":"6448","DOI":"10.18632\/oncotarget.3361","volume":"6","author":"J Li","year":"2015","unstructured":"Li J, Chen Y, Zhu Y et al (2015) Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget 6:6448\u20136458","journal-title":"Oncotarget"},{"key":"5452_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41408-022-00740-3","volume":"12","author":"J Li","year":"2022","unstructured":"Li J, Han Q, Huang Y et al (2022) High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study. Blood Cancer J 12:145","journal-title":"Blood Cancer J"},{"key":"5452_CR19","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405","journal-title":"Blood"},{"key":"5452_CR20","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/ajh.25929","volume":"95","author":"I Aldoss","year":"2020","unstructured":"Aldoss I, Zhang J, Mei M et al (2020) Venetoclax and hypomethylating agents inFLT3 -mutated acute myeloid leukemia. Am J Hematol 95:1193\u20131199","journal-title":"Am J Hematol"},{"key":"5452_CR21","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1158\/1078-0432.CCR-21-3405","volume":"28","author":"M Konopleva","year":"2022","unstructured":"Konopleva M, Thirman MJ, Pratz KW et al (2022) Impact ofFLT3 Mutation on outcomes after venetoclax and azacitidine for patients with treatment-na\u00efve acute myeloid leukemia. Clin Cancer Res 28:2744\u20132752","journal-title":"Clin Cancer Res"},{"key":"5452_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A et al (2020) Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 135:791\u2013803","journal-title":"Blood"},{"key":"5452_CR23","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1158\/1078-0432.CCR-21-3467","volume":"28","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, DiNardo CD, Arellano ML et al (2022) Impact of venetoclax and azacitidine in treatment-na\u00efve patients with acute myeloid leukemia andIDH1\/2 Mutations. Clin Cancer Res 28:2753\u20132761","journal-title":"Clin Cancer Res"},{"key":"5452_CR24","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1182\/bloodadvances.2019000090","volume":"3","author":"SS Patel","year":"2019","unstructured":"Patel SS, Ho C, Ptashkin RN et al (2019) Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Adv 3:1540\u20131545","journal-title":"Blood Adv"},{"key":"5452_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1182\/blood.2020008211","volume":"137","author":"B Falini","year":"2021","unstructured":"Falini B, Brunetti L, Martelli MP (2021) How I diagnose and treat NPM1-mutated AML. Blood 137:589\u2013599","journal-title":"Blood"},{"key":"5452_CR26","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/bloodadvances.2020003734","volume":"5","author":"M Stahl","year":"2021","unstructured":"Stahl M, Menghrajani K, Derkach A et al (2021) Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed\/refractory AML. Blood Adv 5:1552\u20131564","journal-title":"Blood Adv"},{"key":"5452_CR27","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00277-020-03911-z","volume":"99","author":"YW Wang","year":"2020","unstructured":"Wang YW, Tsai CH, Lin CC et al (2020) Cytogenetics and mutations could predict outcome in relapsed and refractory acute myeloid leukemia patients receiving BCL-2 inhibitor venetoclax. Ann Hematol 99:501\u2013511","journal-title":"Ann Hematol"},{"key":"5452_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/joim.13581","volume":"293","author":"G Weng","year":"2023","unstructured":"Weng G, Zhang Y, Yu G et al (2023) Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia. J Intern Med 293:329\u2013339","journal-title":"J Intern Med"},{"key":"5452_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","volume":"16","author":"H Jin","year":"2023","unstructured":"Jin H, Zhang Y, Yu S et al (2023) Venetoclax Combined with azacitidine and homoharringtonine in relapsed\/refractory AML: a multicenter, phase 2 trial. J Hematol Oncol 16:42","journal-title":"J Hematol Oncol"},{"key":"5452_CR30","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3109\/10428194.2011.606382","volume":"53","author":"HK Al-Ali","year":"2011","unstructured":"Al-Ali HK, Jaekel N, Junghanss C et al (2011) Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I\/II study. Leuk Lymphoma 53:110\u2013117","journal-title":"Leuk Lymphoma"},{"key":"5452_CR31","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1200\/JCO.2009.23.9178","volume":"28","author":"AF Cashen","year":"2010","unstructured":"Cashen AF, Schiller GJ, O\u2019Donnell MR, Dipersio JF (2010) Multicenter, phase II study of decitabine for the first-line treatment of older patients with Acute myeloid leukemia. J Clin Oncol 28:556\u2013561","journal-title":"J Clin Oncol"},{"key":"5452_CR32","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Kuo C et al (2012) Multicenter, Randomized, open-label, phase iii trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670\u20132677","journal-title":"J Clin Oncol"},{"key":"5452_CR33","doi-asserted-by":"publisher","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","volume":"5","author":"EM Cherry","year":"2021","unstructured":"Cherry EM, Abbott D, Amaya M et al (2021) Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv 5:5565\u20135573","journal-title":"Blood Adv"},{"key":"5452_CR34","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, Wang Y, Huang F et al (2020) Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol 21:1201\u20131212","journal-title":"Lancet Oncol"},{"key":"5452_CR35","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nm.4484","volume":"24","author":"NR Mathew","year":"2018","unstructured":"Mathew NR, Baumgartner F, Braun L et al (2018) Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med 24:282\u2013291","journal-title":"Nat Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05452-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05452-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05452-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T05:04:51Z","timestamp":1699679091000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05452-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["5452"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05452-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"assertion":[{"value":"15 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the ethics committee of Shenzhen Second People\u2019s Hospital and conducted in accordance with the Helsinki declaration. This retrospective study received a waiver for informed consent from the ethics committee of Shenzhen Second People\u2019s Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}